|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM302908102 |
| 003 |
DE-627 |
| 005 |
20231227130129.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2019 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1021/acs.langmuir.9b03322
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1224.xml
|
| 035 |
|
|
|a (DE-627)NLM302908102
|
| 035 |
|
|
|a (NLM)31686512
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Zhang, Yueheng
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Amphiphilic Polypeptoids Rupture Vesicle Bilayers To Form Peptoid-Lipid Fragments Effective in Enhancing Hydrophobic Drug Delivery
|
| 264 |
|
1 |
|c 2019
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 22.07.2020
|
| 500 |
|
|
|a Date Revised 13.12.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Peptoids are highly biocompatible pseudopeptidic polyglycines with designable substituents on the nitrogen atoms. The therapeutic and drug-carrying potential of these materials requires a fundamental understanding of their interactions with lipid bilayers. In this work, we use amphiphilic polypeptoids with up to 100 monomeric units where a significant fraction (26%) of the nitrogen atoms are functionalized with decyl groups (hydrophobes) that insert into the lipid bilayer through the hydrophobic effect. These hydrophobically modified polypeptoids (HMPs) insert their hydrophobes into lipid bilayers creating instabilities that lead to the rupture of vesicles. At low HMP concentrations, such rupture leads to the creation of large fragments which remarkably anchor to intact vesicles through the hydrophobic effect. At high HMP concentrations, all vesicles rupture to smaller HMP-lipid fragments of the order of 10 nm. We show that the technique for such nanoscale polymer-lipid fragments can be exploited to sustain highly hydrophobic drug species in solution. Using the kinase inhibitor, Sorafenib as a model drug, it is shown that HMP-lipid fragments containing the drug can efficiently enter a hepatocellular carcinoma cell line (Huh 7.5), indicating the use of such fragments as drug delivery nanocarriers
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, Non-P.H.S.
|
| 650 |
|
7 |
|a Antineoplastic Agents
|2 NLM
|
| 650 |
|
7 |
|a Drug Carriers
|2 NLM
|
| 650 |
|
7 |
|a Lipid Bilayers
|2 NLM
|
| 650 |
|
7 |
|a Liposomes
|2 NLM
|
| 650 |
|
7 |
|a Peptoids
|2 NLM
|
| 650 |
|
7 |
|a Phosphatidylcholines
|2 NLM
|
| 650 |
|
7 |
|a Protein Kinase Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Surface-Active Agents
|2 NLM
|
| 650 |
|
7 |
|a Sorafenib
|2 NLM
|
| 650 |
|
7 |
|a 9ZOQ3TZI87
|2 NLM
|
| 700 |
1 |
|
|a Heidari, Zahra
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Su, Yang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yu, Tianyi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xuan, Sunting
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Omarova, Marzhana
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Aydin, Yucel
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dash, Srikanta
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Donghui
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a John, Vijay
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Langmuir : the ACS journal of surfaces and colloids
|d 1992
|g 35(2019), 47 vom: 26. Nov., Seite 15335-15343
|w (DE-627)NLM098181009
|x 1520-5827
|7 nnns
|
| 773 |
1 |
8 |
|g volume:35
|g year:2019
|g number:47
|g day:26
|g month:11
|g pages:15335-15343
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1021/acs.langmuir.9b03322
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_721
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 35
|j 2019
|e 47
|b 26
|c 11
|h 15335-15343
|